NAGE logo

Niagen Bioscience Stock Price

Symbol: NasdaqCM:NAGEMarket Cap: US$713.6mCategory: Pharmaceuticals & Biotech

NAGE Share Price Performance

US$9.64
6.95 (258.36%)
35.3% undervalued intrinsic discount
US$14.90
Fair Value
US$9.64
6.95 (258.36%)
35.3% undervalued intrinsic discount
US$14.90
Fair Value
Price US$9.64
AnalystConsensusTarget US$14.90

NAGE Community Narratives

AN
AnalystConsensusTarget
AnalystConsensusTarget·Updated
Fair Value US$14.90 35.3% undervalued intrinsic discount

Niagen IV Launch And E-commerce Growth Will Strengthen Future Prospects

2users have liked this narrative
1users have commented on this narrative
14users have followed this narrative

Recent NAGE News & Updates

No updates

Niagen Bioscience, Inc. Key Details

US$107.9m

Revenue

US$40.5m

Cost of Revenue

US$67.5m

Gross Profit

US$53.4m

Other Expenses

US$14.1m

Earnings

Last Reported Earnings
Mar 31, 2025
Next Reporting Earnings
Aug 06, 2025
Earnings per share (EPS)
0.18
Gross Margin
62.51%
Net Profit Margin
13.07%
Debt/Equity Ratio
0%

Niagen Bioscience, Inc. Competitors

 
 
 
 
 
 
 
 
 
 
 
 

About NAGE

Founded
1999
Employees
104
CEO
Robert Fried
WebsiteView website
www.niagenbioscience.com

Niagen Bioscience, Inc. operates as a bioscience company engages in developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; nicotinamide adenine dinucleotide (NAD+) test kits to healthcare practitioners; and develops and commercializes proprietary-based ingredient technologies, including food-grade, Niagen, and pharmaceuticalgrade Niagen and supplies these ingredients as raw materials to the manufacturers of consumer products. The company also offers the supply of phytochemical reference standards and other research and development services. In addition, it commercializes NAD+ precursor nicotinamide riboside as the flagship ingredient under NIAGEN brand name. The company distributes TRU NIAGEN products direct to consumers through its propriety e-commerce platform TRUNIAGEN.com, Amazon, ShopHQ, and other internet marketplaces, as well as specialty retailers and direct healthcare practitioners in the United States. The company was formerly known as ChromaDex Corporation and changed its name to Niagen Bioscience, Inc. in March 2025. Niagen Bioscience, Inc. was founded in 1999 and is headquartered in Los Angeles, California.

U.S. Market Performance

  • 7 Days: -1.2%
  • 3 Months: 13.1%
  • 1 Year: 22.8%
  • Year to Date: 7.3%
Over the last 7 days, the market has dropped 1.2%, driven by a loss of 4.7% in the Consumer Discretionary sector. In contrast to the last week, the market is actually up 23% over the past year. Earnings are forecast to grow by 15% annually. Market details ›
This week, we’re diving deeper into the world of agentic AI. We’re zeroing in on the core technologies that make these intelligent agents actually reliably work. We explore what all this could mean for software, start-ups, and most importantly, the opportunities and risks each industry faces by adopting Agentic AI.
Continue reading